Daniel Allen Gold Sells 12,380 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Daniel Allen Gold sold 12,380 shares of the company’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $35.28, for a total transaction of $436,766.40. Following the completion of the transaction, the director owned 13,689,166 shares in the company, valued at approximately $482,953,776.48. This trade represents a 0.09% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Daniel Allen Gold also recently made the following trade(s):

• On Monday, June 29th, Daniel Allen Gold sold 800,000 shares of Roivant Sciences stock. The shares were sold at an average price of $34.55, for a total transaction of $27,640,000.00.
• On Friday, June 26th, Daniel Allen Gold sold 625,783 shares of Roivant Sciences stock. The stock was sold at an average price of $34.00, for a total transaction of $21,276,622.00.

Roivant Sciences Price Performance

Shares of NASDAQ:ROIV opened at $35.03 on Thursday. The company’s fifty day moving average price is $30.00 and its 200-day moving average price is $27.11. The firm has a market capitalization of $25.20 billion, a price-to-earnings ratio of -58.38 and a beta of 1.10. Roivant Sciences Ltd. has a one year low of $10.70 and a one year high of $35.90.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings data on Wednesday, May 20th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.57. Roivant Sciences had a negative net margin of 3,629.19% and a negative return on equity of 20.54%. The company had revenue of $2.52 million during the quarter, compared to the consensus estimate of $3.41 million. During the same period in the previous year, the firm posted ($0.29) EPS. As a group, equities research analysts expect that Roivant Sciences Ltd. will post -1.83 EPS for the current year.

Institutional Investors Weigh In On Roivant Sciences

A number of hedge funds and other institutional investors have recently modified their holdings of ROIV. SBI Securities Co. Ltd. grew its position in Roivant Sciences by 1,740.3% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock worth $27,000 after acquiring an additional 1,166 shares during the last quarter. Allworth Financial LP boosted its stake in shares of Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after purchasing an additional 583 shares during the period. Kestra Advisory Services LLC purchased a new stake in shares of Roivant Sciences during the fourth quarter valued at approximately $47,000. Parallel Advisors LLC grew its holdings in shares of Roivant Sciences by 33.7% in the first quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock worth $57,000 after purchasing an additional 520 shares during the last quarter. Finally, CIBC Private Wealth Group LLC grew its holdings in shares of Roivant Sciences by 7,614.3% in the fourth quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company’s stock worth $59,000 after purchasing an additional 2,665 shares during the last quarter. Institutional investors own 64.76% of the company’s stock.

Analysts Set New Price Targets

ROIV has been the subject of a number of research reports. Weiss Ratings cut Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. TD Cowen raised their price objective on Roivant Sciences from $38.00 to $41.00 and gave the company a “buy” rating in a report on Thursday, May 21st. Piper Sandler restated an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, May 21st. Leerink Partners set a $42.00 target price on Roivant Sciences in a research note on Thursday, May 21st. Finally, Guggenheim upped their target price on Roivant Sciences from $30.00 to $36.00 and gave the stock a “buy” rating in a research note on Tuesday, May 26th. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $33.59.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.